The US FDA-approved anti-inflammatory drug cromolyn sodium has been demonstrated to delay disease progression in an ALS mouse model.
This week in industry we’re taking a look at the discontinuation of umibecestat and Acthar® Gel for Alzheimer’s and ALS, respectively, as well as the drug discovery shift from the amyloid approach in the Alzheimer’s field.
A preliminary clinical study has demonstrated that the experimental drug tofersen may be effective in the treatment of a genetic form of ALS.
Researchers have demonstrated that there may be a link between playing professional soccer and developing ALS. Soccer players studied were almost twice as likely to develop the disease than the general population.
Researchers have revealed that RNA-binding proteins accumulate in the brains of people with non-heritable amyotrophic lateral sclerosis and frontotemporal dementia.
A potential new therapeutic for inherited amyotrophic lateral sclerosis, which extended survival and reversed fatal neuromuscular damage in rodents, has entered Phase I/II clinical trials.